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Introduction:  During  the 2009–2010  H1N1  pandemic,  vaccine  in  short  supply  was  allocated  to  states
pro  rata  by  population,  yet  the  vaccination  rates  of adults  differed  by  state.  States  also  differed  in  their
campaign  processes  and  decisions.  Analyzing  the  campaign  provides  an  opportunity  to  identify  speciﬁc
approaches  that  may  result  in  higher  vaccine  uptake  in a future  event  of  this  nature.
Objective: To  determine  supply  chain  and  system  factors  associated  with  higher  state  H1N1  vaccination
coverage  for  adults  in  a system  where  vaccine  was  in  short  supply.
Methods: Regression  analysis  of  factors  predicting  state-speciﬁc  H1N1  vaccination  coverage  in adults.
Independent  variables  included  state  campaign  information,  demographics,  preventive  or health-seeking
behavior,  preparedness  funding,  providers,  state  characteristics,  and  H1N1-speciﬁc  state  data.
Results: The  best model  explained  the  variation  in state-speciﬁc  adult  vaccination  coverage  with  an
adjusted  R-squared  of 0.76.  We  found  that  higher  H1N1  coverage  of adults  is  associated  with  program
aspects  including  shorter  lead-times  (i.e.,  the number  of  days  between  when  doses  were  allocated  to  a
state  and  were  shipped,  including  the  time  for states  to order  the  doses)  and  less  vaccine  directed  to
specialist  locations.  Higher  vaccination  coverage  is also  positively  associated  with  the maximum  number
of  ship-to  locations,  past  seasonal  inﬂuenza  vaccination  coverage,  the percentage  of women  with  a  Pap
smear,  the  percentage  of  the population  that is Hispanic,  and  negatively  associated  with  a long  duration
of  the  epidemic  peak.
Conclusion: Long  lead-times  may  be  a function  of system  structure  or of efﬁciency  and  may  suggest
monitoring  or redesign  of distribution  processes.  Sending  vaccine  to sites  with  broad  access  could  be
useful  when  covering  a general  population.  Existing  infrastructure  may  be reﬂected  in the  maximum
number  of  ship-to  locations,  so strengthening  routine  inﬂuenza  vaccination  programs  may  help  during
emergency  vaccinations  also.  Future  research  could  continue  to inform  program  decisions.
 201©
. Introduction
The novel H1N1 inﬂuenza virus was detected in the United
tates in April 2009. Worldwide, a pandemic was  declared, and national public health emergency was announced in the United
tates. In the US, plans were made for a national vaccination cam-
aign to be rolled out in Fall 2009, when the pandemic H1N1
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vaccine would be available. The campaign was implemented as a
public–private partnership, with federal purchase of the vaccine.
The Centers for Disease Control and Prevention (CDC) allocated vac-
cine pro rata to states by total population as the vaccine became
available. States determined how vaccine would be allocated in
their jurisdiction and either retained control of vaccine allocation
to individual providers at the central level or delegated fully or
partially to local jurisdictions. States or local jurisdictions invited
providers to participate in the program and vaccine was shipped
to designated providers through a centralized distribution process
supervised by the CDC that built on an existing contract for man-
agement and distribution of vaccines in the Vaccine for Children
Open access under CC BY-NC-ND license.(VFC) program. Fig. 1 shows a basic scheme of the supply chain for
H1N1 vaccine from manufacturer to provider.
State decisions about where to direct vaccine were guided
by recommendations of the CDC’s Advisory Committee on
 license.
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iig. 1. Illustrates the supply chain for H1N1 vaccine during the 2009–2010 pandem
ocal  providers, where states selected different distribution processes and locations
mmunization Practices (ACIP) [6], which recommended that the
accine be initially directed to: pregnant women, persons who  live
ith or provide care for infants aged <6 months, health-care and
mergency medical services personnel who have direct contact
ith patients or infectious material, all people 6 months to 24 years
f age, and persons aged 25 through 64 years with certain health
onditions (“high-risk”). The recommendations also provided fur-
her speciﬁcation of priority groups in the event of vaccine shortage
nd stated that decisions to broaden availability of vaccine should
e made at the local level.
Overall, more than 120 million doses of vaccine were distributed
o over 70 thousand locations by April 2010 [4,8,9] and 80.8 million
eople reported having been vaccinated [10]. The vaccine sup-
ly was insufﬁcient to meet demand initially, and became more
lentiful after Thanksgiving, a time when demand for inﬂuenza vac-
ination traditionally slows. Despite the pro rata allocation of H1N1
accine [11], state level vaccine coverage rates indicate that there
ere great differences in coverage across the states even when
accine was in short supply. By the end of January 2010 [1], the
overage of adults ranged from 8.7% to 34.4% (Fig. 2).
States  varied in their approaches to implementing their H1N1
accination programs in an unprecedented situation. While the lit-
rature addressed factors related to uptake of seasonal inﬂuenza
accine at the individual level [12,13], states and regions used their
est judgment and knowledge of their jurisdictions to guide their
ecisions on distribution and system design, given the lack of sci-
ntiﬁc evidence in that area. The purpose of this study was to
etermine supply chain and system factors associated with H1N1
overage rates at the state-wide level for adults in order to inform
uture events of this nature.
We  hypothesized that characteristics of the vaccine supply
hain in each state and decisions around targeting vaccine could
redict uptake. One classic supply chain study, for example, has
emonstrated that a product stocked in a large number of loca-
ions increases the probability that a particular location will be
tocked out, and may  also reduce the distance traveled by the ﬁnal
onsumer [14]. Some of these characteristics of the state vaccine
upply included the number of locations where vaccine was avail-
ble, prioritization of the ACIP-recommended target groups, the
ype of providers to whom vaccine was directed, and the lead-
ime between vaccine allocation and availability in a state, which
argely reﬂects differences in states’ ordering processes. Because
ther factors affect uptake, as evidenced by state-to-state variation
n seasonal inﬂuenza coverage and individual-level studies [15–18],
nderlying population differences such as demographic charac-
eristics, utilization of preventive health services, and healthcare
nfrastructure were also examined. It is relevant to mention thatccination campaign, e.g., from manufacturers to state health departments (HDs) to
individual-level  studies differ from those with a regional or ecolog-
ical view. Others have used this ecological approach in the analysis
of other health-related problems such as water ﬂuoridation and
tooth decay [19,20]. Data from the centralized distribution system
on vaccine shipments from October 5, 2009 through December 9,
2009 were made available for analysis, thus allowing us to focus the
analysis on the period during which vaccine was in short supply.
2.  Methods
2.1. Design
We  examined the relationship between state vaccination rates
in persons 18 and over with variables covering population and
health-related state characteristics and state-speciﬁc vaccination
campaign information.
2.2.  Data
The outcome measure is state estimates of vaccination cover-
age, as calculated by the CDC [1]. Participants 18 and over on the
Behavioral Risk Factor Surveillance System (BRFSS) and National
H1N1 Flu Survey (NHFS) were asked if they had received an H1N1
vaccine during October 2009–January 2010.
2.2.1. Population and state characteristics
From the Census, we  identiﬁed population [3] characteris-
tics including population size and density, age groups, education,
race/ethnicity, income and poverty, births, and family composi-
tion [21]. We  also examined measures of income inequalities [22],
and segregation and disparities [23]. We  extracted the geographi-
cal area, number of counties, and federal government expenditure
per capita from the Census.
We estimated the total number of healthcare practitioners [24],
the number of active physicians [25] per thousand population
(PTP), and the percentage of the population who have not visited a
doctor in the last year because of cost [2]. We  determined whether
states were characterized by state control, local control, or by infer-
ence, mixed control, from the 2008 National Proﬁle of Local Health
Departments [26].
To  capture health-seeking behaviors and use of preventive ser-
vices, we obtained state-speciﬁc inﬂuenza vaccination rates for
previous seasons [7], the percent of women who had a Pap smear
in the past 3 years [2], and population percentages associated with
various health conditions [27].
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Fig. 2. H1N1 vaccination coverage of ad
.2.2. State-speciﬁc vaccination programs and surveillance
We  obtained information on the emergency funding provided to
tates for the H1N1 pandemic from CDC reports including amounts
pent or unobligated for assessment, planning and response
28,29].
Reports from the Outpatient Inﬂuenza-like Illness Network
ILINet) [5] obtained from the CDC, provided weekly values for
he proportion of outpatient visits for inﬂuenza-like illness (ILI) at
articipating providers, by state, from which we calculated several
easures including the percentage of weeks with % ILI above 2.3,
fter week 30.
We  extracted information on state processes and decisions from
 survey [30] of immunization program managers conducted by
he University of Michigan to provide CDC with situational aware-
ess during the H1N1 campaign on allocation of vaccine, expansion
ate beyond priority groups, whether a state focused on school
accination or not, and vaccine distribution methods.
We  obtained information on the amount of vaccine allocated
o each state over time, the maximum number of provider sites
o which each state could have vaccine shipped through the cen-
ralized distribution system (“ship-to” sites) [8], and self-reported
ata from states on doses distributed to or administered in public
ettings [31].
Information on the date, address, and number of doses shipped
o each location, from the beginning of the campaign through
ecember 9, 2009 (which covers the major shortage period) was
btained from the centralized distribution shipping records [4]. We
alculated measures such as the number of unique sites to which
accine was shipped (ship-to sites), the average number of ship-
ents per site, the variation in doses PTP across counties within a
tate, and the lead-time from allocation to shipment (i.e., the aver-
ge number of days between when a state received an allocation
nd ordered the vaccine, plus the average number of days doses
pent between order placement and shipment). Shipments during
his time period were sent overnight to their destination (regard-
ess of distance), to arrive when receiving locations within the state
ere open.
We  categorized shipments (over 75%) by the type of providerhrough a series of targeted queries we generated. Thus, we cal-
ulated proportion of shipments or doses PTP to providers focused
n children, primary care, county health departments, unclassiﬁed
edical doctors, internists, specialists, long-term care, veterans,MWR 59 (12 ):363-8
 state as of the end of January 2010 [1].
urgent  care, hospitals, clinics, pharmacies, jails, military, govern-
ment, universities, and nursing homes. The category of “specialists”
includes providers that we  could identify as associated with car-
ing for the ACIP population categorized as high-risk because of
health conditions such as asthma, heart disease, diabetes, etc.
We also combined these in several subgroupings driven by like
characteristics that might explain differences in coverage: e.g.,
general internists and specialists combined (internists and spe-
cialists can be grouped because both serve adults; however, while
internists may  provide primary care, adults may  be less likely to
visit internists or specialists during a short campaign); targeted
access (doses sent to long term care, internists, specialists, nurs-
ing homes, and children); and general access locations (primary
care, MDs  that could not be classiﬁed by specialization, counties,
hospitals, urgent care, clinics, or pharmacies).
2.3. Analysis
Using cross-sectional data, we developed a regression model to
predict vaccine coverage in adults, as of the end of January 2010, for
DC and each state [1]. In a separate analysis, we constructed distinct
models for children (6 m to 17 y) and high risk adults (25–64 with a
chronic condition) because we  expected factors affecting coverage
to differ across groups; we  present those analyses in a separate
paper.
We calculated simple descriptive statistics (means, standard
deviations, proportions, and measures of association including
Pearson’s correlation). The primary technique used for modeling
was multivariate linear regression (ordinary least squares) with
transformations speciﬁed when used. Data were linearly scaled to
values in [0,1] before performing regressions.
Variable selection is a challenging problem [32], and our analy-
sis poses additional difﬁculties because of high correlations among
variables. Statistical research [33,34] sets basic principles for deal-
ing with these problems. We performed stepwise selection of
variables to better prevent introducing high correlations in the
model. We  explored variable inclusion both based on high associ-
ation with the dependent variable and incorporating or removing
one variable at a time according with their potential to improve
the model (using the Akaike information criterion [35]) and
their p-value, with many different combinations of starting vari-
ables explored (a deeper explanation of the variable selection
accin
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ethodology can be found in the Supplementary Methods Section
le). The maximum number of dependent data points was 51 with
 large number of variables to consider; however, the best models
ad less than ten variables each. We  kept “outliers” in the analysis
ecause we consider they speak to real extreme state cases and not
o data deformities, and examined quantile–quantile (Q–Q) plots to
etermine whether additional transformations were needed. Mod-
ls were evaluated on adjusted R-square values and the F-statistic,
ith an individual variable evaluated on its p-value (below 5%).
he regressions were performed with R statistical software package
ersion 2.11.1 [36]. Some descriptive statistics were calculated in
icrosoft Excel versions 11 and 12.
. Results
Seven variables including lead-time from allocation to ordering
nd shipment, the maximum number of ship-to sites per thou-
and population, past seasonal inﬂuenza coverage for non-high
isk adults age 18–49, percentage of doses categorized as sent to
nternists and specialists, percentage of women 18 and older with
 Pap smear in the last three years, percentage of weeks with ILI
bove 2.3 after week 30, and the percentage of residents of Hispanic
r Latino origin were signiﬁcant for predicting vaccination coverage
n adults (Table 1). The best model found explained the variation
n state-speciﬁc adult vaccination coverage with an adjusted R-
quared of 0.76 and a p-value close to 0 (Table 2).
For supply decisions, a long lead-time was associated with lower
overage, and the associated coefﬁcient has a relatively large mag-
itude. Additional analysis of lead-time indicated that a state’s
elative lag tended to be consistent throughout the months con-
idered. We  also found that lead-time is correlated with some
ariables related to shipment choice (e.g., positively with use of
hird parties for distribution, and negatively with shipments per
hip-to site). The vaccine allocated to internists and specialists as
 percentage of the total shipped was negatively associated with
overage, and having a large number of maximum ship-to sites was
ositively associated with coverage.
Vaccination coverage was positively associated with past
nﬂuenza vaccination coverage; while we found a strong asso-
iation, there were several other effects that were also large in
agnitude. Coverage was also positively associated with the per-
entage of women with a Pap smear, and the percent of the
opulation that is Hispanic. A long duration of ILI severity peaks
deﬁned by the percentage of weeks in the Fall with percent
LI more than 2.3) was negatively associated with coverage. To
rovide more information on our modeling, Supplementary Table
 presents examples of other variables highly correlated with those
actors in our ﬁnal model.
.  Discussion
In an effort to identify lessons learned for a future pandemic
accination event, we sought to identify factors related to vacci-
ation program decisions and processes that may  have facilitated
r hindered vaccine uptake. Program factors that were associated
ith vaccine uptake included the lead-time between allocation
nd ordering and shipping, and the type of providers receiving
accine. Factors not related to program decisions such as health-
eeking behaviors and population characteristics also contributed
o predicting state-to-state variation, as would be expected given
aseline variation in previous inﬂuenza vaccination coverage [7]
nd other ﬁndings [37–39].
Lead-time  from allocation to ordering and shipment was nega-
ively associated with vaccination coverage. Steps in the ordering
rocess varied by state and could include requesting speciﬁc orderse 32 (2014) 3088–3093 3091
from providers (in advance of allocation or after receiving an allo-
cation), decisions on where to distribute vaccine, and notiﬁcation
of decisions. States also determined the frequency of ordering, the
day(s) of the week to order, the number of providers participat-
ing or receiving vaccine, and the overall process to follow, all of
which could affect the lead-time. Because of the initial focus on
ACIP-deﬁned target groups, in many states adults without high
risk conditions were not eligible for vaccination until demand for
vaccine had already begun to wane. Delays in allocated vaccine
being made available to the population could have resulted in less
vaccination. On the other hand, lags in ordering could be a con-
sequence of decreasing demand, and thus be a result of lower
vaccination rates rather than a cause. The tendency for lags in
ordering to be consistent for a given state throughout the time
period studied, suggests the lead-time resulted from the ordering
process.
We also found a relationship with the type of providers or loca-
tions to which vaccine was  directed. For adults, vaccine sent to
providers with specialized services or patient base was associated
with lower coverage. This could be because not all adults visit
internists or specialists frequently enough to be vaccinated in this
time period; it could also be that those providers had less focus tra-
ditionally on vaccinating so patients looked elsewhere for vaccine.
Overall, only a small proportion of vaccine was  sent to internists
and specialists.
One  variable may  be more a measure of health infrastructure
than the supply chain system itself. In particular, the maximum
number of sites to which vaccine could be directly shipped through
the centralized distribution system) was positively associated with
vaccination coverage. (In contrast, another variable measured the
actual ship-to sites registered or used within a state.) The maxi-
mum number of ship-to sites allowed for each state was  based on
a formula that included the population size as well as the number
of existing VFC providers. A high number of VFC sites per capita
could be a reﬂection of a more robust infrastructure for providing
vaccine.
State factors unrelated to supply chain decisions about H1N1
vaccine were also related to coverage, speciﬁcally included usage
of health services. Others have found that for an individual, past
inﬂuenza vaccination is a strong predictor of annual inﬂuenza vac-
cination [12,17]: a relationship that may  reﬂect both differences in
infrastructure and differences in attitudes. The ﬁnding in this paper
demonstrates that pandemic inﬂuenza vaccination also is asso-
ciated with uptake of seasonal vaccine. The association between
coverage rates and rates of receipt of Pap smear may  be a reﬂection
of utilization of preventive care, although no further analysis could
be carried out to determine if this effect was present only among
women.
Some characteristics of the epidemic may  have also inﬂuenced
coverage. For states where the epidemic lasted longer, coverage
was lower. This could be because vaccine was made available to
non-high risk adults later in the season, and persons may  have
reasoned that they had likely been exposed to the disease already
and did not need vaccination. Conversely, the positive association
between coverage and the percentage of Hispanics may reﬂect
higher vaccination rates in communities with greater perceived
risk [40] due to the virus emerging from Mexico. In general, His-
panic populations did not have a higher coverage than the overall
average [41].
This  study had several limitations. First, cross sectional stud-
ies and regressions are useful for identifying associations, but they
have a number of intrinsic limitations, for example, we cannot
determine causality, and for complex cases like the one analyzed
other good regression models may  also exist for the same set of
variables. Supplementary Table 2 presents a summary of variables
highly correlated with those in the model. Secondly, the ecological
3092 C. Davila-Payan et al. / Vaccine 32 (2014) 3088–3093
Table 1
List  of variables in the best model, including the dependent variable at the top. Table shows the variable’s name, description (with reference for the data), average value,
standard deviation, and maximum and minimum values.
Variable Description Reference Average Std. Dev. Maximum Minimum
Dependent Coverage on persons
aged  ≥ 18 yrs
MMWR  [1] 19.9 5.3 34.4 8.7
Indep1  Percent of women  age 18 and
older who  report having had a
Pap smear within the last three
years, 2008
State health facts [2] 82.7 2.9 88.9 74.1
Indep2  Resident population: Hispanic
or  Latino Origin, percent (July 1
2009 – estimate)
Census [3] 9.8 9.6 44.9 1.1
Indep3  Average days from allocation
to  shipment of vaccine
CDC  shipments report (calculation) [4] 6.3 2.3 12.5 2.1
Indep4  Percentage of weeks with % ILI
above 2.3, after week 30
Report  CDC [5] 42 24.4 97.4 10.3
Indep5  Seasonal inﬂuenza coverage for
non-high risk adults 18–49 yrs
on the 2007–2008 season
CDC  inﬂuenza vaccination coverage [7] 22.6 5.1 37.8 11.9
Indep6  Maximum number of ship-to
sites per state per thousand
population
Report  CDC (calculation) [8] 0.5 0.1  0.74 0.00a
Indep7 Percentage of doses
categorized  as sent to
internists  or specialistsb
Report CDC (calculation) [4] 1.17 1.08 6.07 0a
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AValue for Alaska where all vaccine was shipped to a single warehouse then dist
b Overall, approximately 75% of shipments were categorized by type of provider.
pproach followed does not point to individual characteristics of
he population but to state-level conditions, and does not analyze
otential variations within states. Third, the data from the cen-
ralized distribution system covers shipments through December
, 2009, and the outcome measure is vaccination coverage as of
he end of January 2010. The gap may  not be as large as it seems,
ince coverage for adults increased from 17.3% (adults ≥ 19 [42])
t the end of December 2009 to around 18.2% (adults ≥ 18, derived
rom state-speciﬁc rates [1] and adult populations [3]) at the end of
anuary 2010. Additionally, the number of people vaccinated by the
nd of January (74M) is approximately the same as the total vac-
ines shipped by December 9 (72M) though this comparison does
ot take into account receipt of second doses by children. Fourth,
he vaccine shipment data represented shipment location, which
s not necessarily the same as the ﬁnal place of administration of
accine (e.g., vaccine may  have been distributed from a third party
istributors or local health department to providers). As a result,
he number of locations of administration may  be underestimated,
r the provider type may  be misclassiﬁed. Fifth, some shipping data
ere missing or potentially inaccurate. Provider type could not be
etermined for 25% of shipments, the information on state and local
ecisions and processes was not always complete, and databases
ould have errors. Finally, the number of dependent variable
able 2
egression results for predicting the state level vaccination coverage for the adult popul
he  variable’s coefﬁcient, coefﬁcient’s standard error, coefﬁcient’s t-value, and results of t
Variable Short description Estimate 
(Intercept) 2.66E−16
Indep2  % Hispanic 0.378 
Indep5  Past inﬂuenza coverage 0.3599 
Indep1  % women  w/Pap 0.3002 
Indep6  Max  # sites 0.1807 
Indep7  % to specialists −0.295 
Indep4  % weeks ILI high −0.4366 
Indep3  Lead-time −0.4419 
igniﬁcance codes: 0 < ‘***’ < 0.001 < ‘**’ < 0.01 < ‘*’ < 0.05.
djusted R-squared: 0.7637, Reg. p-value: 6.035E−13.d to providers by the state.
observations is fairly small (51), and many factors may  potentially
be associated with H1N1 coverage.
The distribution and administration of the H1N1 vaccine was a
test of the health emergency response systems, and it is an oppor-
tunity to identify speciﬁc approaches that may result in higher
vaccine uptake in a future event of this nature. Several of the
ﬁndings warrant further consideration. The ﬁndings suggest that
continued efforts to increase uptake of inﬂuenza vaccination may
result in increased uptake in an emergency response. The negative
association between order lags and coverage is an important aspect
of the supply chain and distribution. It is possible that time lags are
a function of the system design or processes, which would suggest
monitoring and/or designing the system for fast response within
the states in an emergency is needed. There can be many decisions
made at the state level that can affect lead-time including order-
ing frequency, number of delivery locations, on which days orders
were placed, use of third parties, etc. Further study would be useful
in this area. Our results on type of location to which vaccine was
directed may  provide some guidance on increasing coverage, e.g., in
a  campaign with limited resources and time pressures, sending to
general access or public locations may  be beneﬁcial. As more adult
and specialty providers, including pharmacies, take on the role as
vaccinators, this strategy may  change. This, too, remains an area
ation. The table contains the variable name, short description, point estimation of
he signiﬁcance test.
Std. error t value Pr(>|t|)
0.06807 3.9E−15 1.00E+00
0.07953 4.753 2.26E−05 ***
0.07928 4.54 0.000045 ***
0.07653 3.923 0.00031 ***
0.07061 2.558 0.01412 *
0.07788 −3.788 0.000468 ***
0.07362 −5.931 4.61E−07 ***
0.07401 −5.97 4.04E−07 ***
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and Hispanic communities: questions and answers; 2010. Available from:C. Davila-Payan et al. / V
here additional analysis is useful, such as collecting information
n shipments by type of provider, examining the small number
f states where registry information records the location of vac-
ine administration, or additional analysis on where vaccination
ccurred for different target groups.
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